MannKind

Yahoo Finance • 21 days ago

Is MannKind Stock a Buy or Sell After the CEO Sold Nearly 66,000 Shares?

Key Points CEO Michael Castagna sold 65,804 shares on Dec. 17, 2025, for a total value of approximately ~$395,482 at a weighted average price around $6.01 per share. This transaction represented 2.56% of Mr. Castagna's direct holdings, re... Full story

Yahoo Finance • last month

Reassessing MannKind (MNKD) Valuation After Recent Share Price Reset

MannKind (MNKD) has been quietly grinding higher, with shares up about 4% over the past week and roughly 5% in the past 3 months, even as the year-to-date return remains negative. See our latest analysis for MannKind. That recent 1 day s... Full story

Yahoo Finance • last month

MannKind Announces U.S. FDA Accepts for Review its Supplemental New Drug Application (sNDA) of FUROSCIX ReadyFlow™ Autoinjector for the Treatment of Edema in Adults with Chronic Heart Failure or Chronic Kidney Disease

If approved, ReadyFlow Autoinjector would deliver an IV-equivalent diuretic dose (subcutaneous furosemide injection 80 mg/ml) in under 10 secondsWould potentially provide a cost-effective and convenient option to address episodes of fluid... Full story

Yahoo Finance • 2 months ago

MannKind Commemorates Alfred E. Mann’s 100th Birthday with New Scholarship Program Supporting Young Adults Living with Diabetes

MannKind $100,000 in scholarship funds to be distributed to at least 10 students living withdiabetes pursuing higher education in life sciences Alfred E. Mann Charities and MannKind are partnering with The Diabetes Link to launch the effo... Full story

Yahoo Finance • 3 months ago

MannKind Corporation to Hold 2025 Third Quarter Financial Results Conference Call on November 5, 2025

DANBURY, Conn. and WESTLAKE VILLAGE, Calif., Oct. 29, 2025 (GLOBE NEWSWIRE) -- MannKind Corporation (Nasdaq: MNKD), announced today that its third quarter 2025 financial results will be released before the market opens on November 5, 202... Full story

Yahoo Finance • 3 months ago

MannKind's Afrezza under supplemental FDA review

[Diagnosis testing of patients.] metamorworks/iStock via Getty Images * MannKind Corporation (MNKD) announced that the U.S. FDA has accepted the supplemental marketing application seeking approval for Afrezza (insulin human) inhalation... Full story

Yahoo Finance • 3 months ago

MannKind Announces U.S. FDA Accepts for Review its Supplemental Biologics License Application (sBLA) for Inhaled Insulin (Afrezza) in Children and Adolescents Aged 4-17 Years Living with Diabetes

If approved, it would be the first needle-free insulin option for pediatric patients in 100+ years of insulin therapysBLA submission based on data from the Phase 3 INHALE-1 study PDUFA target action date of May 29, 2026 WESTLAKE VILLAGE,... Full story

Yahoo Finance • 3 months ago

MannKind Completes Acquisition of scPharmaceuticals, Accelerating Revenue Growth in Cardiometabolic Care

DANBURY, Conn. and BURLINGTON, Mass., Oct. 07, 2025 (GLOBE NEWSWIRE) -- MannKind Corporation (Nasdaq: MNKD) successfully completed the previously announced acquisition of scPharmaceuticals Inc. The acquisition of scPharmaceuticals is ex... Full story

Yahoo Finance • 4 months ago

MannKind Appoints Dr. Ajay Ahuja as Executive Vice President and Chief Medical Officer

WESTLAKE VILLAGE, Calif., Sept. 29, 2025 (GLOBE NEWSWIRE) -- MannKind Corporation (Nasdaq: MNKD), a company focused on the development and commercialization of innovative inhaled therapeutic products and devices for patients with endocri... Full story

Yahoo Finance • 4 months ago

MannKind's Plan of Increasing Revenue Base, Advancing Potential Pipeline Enhances its Value Creation, Oppenheimer Says

MannKind's (MNKD) game plan of enhancing its revenue base, while also advancing a potential pipeline PREMIUM Upgrade to read this MT Newswires article and get so much more. A Silver or Gold subscription plan is required to access premiu... Full story

Yahoo Finance • 4 months ago

There are notable gap-ups and gap-downs in today's session.

The session on Tuesday is off to an intriguing start with several stocks showing significant price gaps. Let's examine the gap up and gap down stocks in today's session. [gap] TODAY'S GAP UP STOCKS TICKER CHANGE COMMENT CARM... Full story

Yahoo Finance • 4 months ago

Tuesday's pre-market session: top gainers and losers

Let's have a look at what is happening on the US markets before the opening bell on Tuesday. Below you can find the top gainers and losers in today's pre-market session. [premarket] PRE-MARKET GAINERS TICKER CHANGE COMMENT CA... Full story

Yahoo Finance • 5 months ago

Why MannKind (MNKD) Is Up 11.7% After Expanding Technosphere Partnership With United Therapeutics

On August 24, 2025, United Therapeutics announced an amendment to its license and collaboration agreement with MannKind, expanding the deal to cover a new development product formulated using MannKind’s Technosphere platform and triggering... Full story

Yahoo Finance • 5 months ago

MannKind Corporation (MNKD) Seeks FDA Pediatric Approval for Afrezza

We recently published 10 Best Biotech Stocks to Buy Under $10.MannKind Corporation stands fifth among them. MannKind Corporation (NASDAQ:MNKD) is a biopharmaceutical company developing inhaled therapeutic products for endocrine and orphan... Full story

Yahoo Finance • 5 months ago

BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: scPharmaceuticals Inc. (Nasdaq – SCPH), Vital Energy, Inc. (NYSE – VTLE), International Money Express, Inc. (Nasdaq - IMXI), HanesBrands Financial Corp. (NYSE - HBI)

BALA CYNWYD, Pa., Aug. 28, 2025 (GLOBE NEWSWIRE) -- Brodsky & Smith reminds investors of the following investigations. If you own shares and wish to discuss the investigation, contact Jason Brodsky (jbrodsky@brodskysmith.com) or Marc Ack... Full story

Yahoo Finance • 5 months ago

MannKind to Present at Upcoming Investor Conferences

DANBURY, Conn. and WESTLAKE VILLAGE, Calif., Aug. 27, 2025 (GLOBE NEWSWIRE) -- MannKind Corporation (Nasdaq: MNKD), a company focused on the development and commercialization of innovative inhaled therapeutic products and devices for pat... Full story

Yahoo Finance • 5 months ago

MannKind rises as United Therapeutics exercises option for second inhalational drug

[Collaboration concept. Colored threads are connected together and the inscription.] designer491/iStock via Getty Images * MannKind Corporation (NASDAQ:MNKD [https://seekingalpha.com/symbol/MNKD]) added ~10% in the morning hours on Wedn... Full story

Yahoo Finance • 5 months ago

MannKind Announces Expansion of United Therapeutics Collaboration for Second Inhaled Therapy

DANBURY, Conn. and BOSTON, Aug. 27, 2025 (GLOBE NEWSWIRE) --  MannKind Corporation (Nasdaq: MNKD) today announced that United Therapeutics Corporation (Nasdaq: UTHR) has exercised its option—granted under the companies’ 2018 license and... Full story

Yahoo Finance • 5 months ago

MannKind stock price target raised to $8 by RBC on scPharmaceuticals deal

Investing.com - RBC Capital raised its price target on MannKind (NASDAQ:MNKD) to $8.00 from $7.00 on Tuesday, while maintaining an Outperform rating following the company’s acquisition of scPharmaceuticals (NASDAQ:SCPH). InvestingPro data... Full story

Yahoo Finance • 5 months ago

Leerink Partners Reiterates a Buy Rating on MannKind Corporation (MNKD), Keeps the PT at $7

MannKind Corporation (NASDAQ:MNKD) is one of the top strong buy stocks under $5 to buy now. On August 8, Leerink Partners analyst Faisal Khurshid reiterated a Buy rating on MannKind Corporation (NASDAQ:MNKD), keeping the price target at $7... Full story